PReduction Device
Heart Failure with preserved Ejection Fraction (HFpEF) - Stage C/D
Pre-clinicalActive
Key Facts
Indication
Heart Failure with preserved Ejection Fraction (HFpEF) - Stage C/D
Phase
Pre-clinical
Status
Active
Company
About Pumpinheart
Pumpinheart is a private, pre-revenue Irish medtech startup targeting the significant unmet need in HFpEF, a prevalent and difficult-to-treat form of heart failure. Its core innovation is the PReduction device, an ECG-gated, transcatheter-implanted pump system powered by a transcutaneous energy transfer system (TETS), currently in the preclinical research phase. The company has garnered notable grant funding, including a €3.14M Disruptive Technologies Innovation Fund award, and has won several startup and innovation awards, positioning it for continued development toward first-in-human trials.
View full company profile